Connect with us


Sanyal Biotechnology begins work on uncovering CBD’s potential

CBD is drawing the attention of not just consumers and law makers, but also firms that want to look into what the compound can do.




The cannabis industry is receiving a massive push with the help of changes to state laws and studies that uncover the secrets of the naturally occurring beneficial compound, cannabidiol (CBD). Research firms are putting the compound into the limelight of their studies, and this could help support both industries in the long run as there will be more reasons for agencies to reconsider their stand on cannabis.

Norfolk-based Sanyal Biotechnology acquired licensing to import CBD for research and clinical trials last May after receiving encouragement from Ontario-based Revive Therapeutics. With the license secure, the company is planning to uncover CBD’s potential in curing obesity and non-alcoholic steatohepatities (NASH), which is a serious case of non-alcoholic fatty liver disease.

Sanyal CEO Rebecca Caffrey says that they never expected to become a part of the industry. She adds that the licensing process with the Virginia Board of Pharmacy and the U.S. Drug Enforcement Agency took a year. It was almost impossible to get a license, she adds, so they opted to get the broadest license available instead.

The final key to unlock cannabis’ potential

The industry needs more studies to back the claims made by many regarding the compound’s benefits. Although it is a far cry from marijuana, CBD is still widely regarded as a controlled substance. In fact, the U.S. Drug Enforcement Administration only recently reclassified the drug into a Schedule 5 substance.

Uncovering the secrets of CBD is also the key to realizing its full potential. There are many individuals who could use the compound in their lives. For instance, athletes can use the compound to relieve themselves of pain. There are also claims that CBD can be used to treat PTSD in veterans.

While CBD is widely regarded as a controlled substance, the compound is reported to help manage pain for athletes and treat PTSD in veterans. (Source)

Another leader in the research and development of CBD

The good thing is that more companies are being drawn into the research and development of CBD. PotNetwork Holdings, Inc. (OTCMKTS:POTN) has been in the industry long enough to know what the general audience wants, and it uses this knowledge to achieve milestones through its subsidiary and distributor, Diamond CBD, Inc.

To meet the demand for quality CBD products, POTN employs the aid of industry professionals and medical experts. This results in amazing products extracted from premium-quality hemp through supercritical CO2 extraction. As it moves forward with its research and development of CBD, POTN will be able to further increase its already expansive line of CBD products.

Diamond CBD’s products are a top choice among consumers. During the World Vapor Expo Industry Showcase at Mana Wynwood in Miami, Florida, the brand was able to draw the attention of countless vape enthusiasts. Part of the company’s product line is vape additives so their presence at the event was well-received since there is also a strong demand for CBD in Florida.

The CBD industry is becoming a success partially because of the companies that dive deep into the potential compound offers. The success of these companies’ research can result in a better understanding of the compound and this is direly needed as other major agencies are to reconsider their view on marijuana.

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

Michael Jermaine Cards is a business executive and a financial journalist, with a focus on IT, innovation and transportation, as well as crypto and AI. He writes about robotics, automation, deep learning, multimodal transit, among others. He updates his readers on the latest market developments, tech and CBD stocks, and even the commodities industry. He does management consulting parallel to his writing, and has been based in Singapore for the past 15 years.